Loading...
•
Mar 31, 2025
Tempus AI Inc Q1 2025 Earnings Report
Tempus AI posted strong revenue growth and margin expansion but remained in net loss.
Key Takeaways
Tempus AI delivered a significant 75.4% revenue growth in Q1 2025, driven by both Genomics and Data & Services segments. Despite a net loss, the company showed operating leverage and improved Adjusted EBITDA. Strategic partnerships with AstraZeneca and Pathos highlight future growth opportunities.
Revenue reached $255.7 million, up 75.4% year-over-year.
Net loss totaled $68 million, impacted by stock compensation and fair value losses.
Adjusted EBITDA improved to ($16.2 million) from ($43.9 million) a year ago.
Secured $200 million in future fees from AstraZeneca and Pathos partnerships.
Revenue by Segment
Forward Guidance
Tempus raised its full-year 2025 revenue guidance to $1.25 billion and expects to achieve positive Adjusted EBITDA.
Positive Outlook
- Raised FY2025 revenue guidance to $1.25B.
- Expects $5M in positive Adjusted EBITDA for 2025.
- Partnerships with AstraZeneca and Pathos will add $200M over 3 years.
- Hereditary and oncology testing volumes continue to grow.
- Gross margins are improving across all segments.
Challenges Ahead
- Net loss of $68M in the quarter.
- High SG&A expenses, including $16M in stock comp.
- Large fair value losses on equity securities.
- Free cash flow was not positive.
- Significant cash burn of $188.5M in Q1 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...